Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolis

Showing results (361-370 of 392) with videos related to

Pageof 40
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 22, 2010
Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel diseaseElizabeth A Worthey, Alan N Mayer, Grant D Syverson, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Pediatrics|June 18, 2014
Effectiveness of anti-TNFα for Crohn disease: research in a pediatric learning health systemChristopher B Forrest, Wallace V Crandall, L Charles Bailey, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Ecological Applications : a Publication of the Ecological Society of America|August 11, 2015
Greenness indices from digital cameras predict the timing and seasonal dynamics of canopy-scale photosynthesisMichael Toomey, Mark A Friedl, Steve Frolking, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Science Translational Medicine|July 19, 2013
Genomics in clinical practice: lessons from the front linesHoward J Jacob, Kelly Abrams, David P Bick, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Pageof 40

Showing results (361-370 of 392) with videos related to

Sort By:
Pageof 40
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 22, 2010
Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel diseaseElizabeth A Worthey, Alan N Mayer, Grant D Syverson, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Lancet (London, England)|July 29, 2017
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trialDavid A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, et al.
Pediatrics|June 18, 2014
Effectiveness of anti-TNFα for Crohn disease: research in a pediatric learning health systemChristopher B Forrest, Wallace V Crandall, L Charles Bailey, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
Ecological Applications : a Publication of the Ecological Society of America|August 11, 2015
Greenness indices from digital cameras predict the timing and seasonal dynamics of canopy-scale photosynthesisMichael Toomey, Mark A Friedl, Steve Frolking, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Science Translational Medicine|July 19, 2013
Genomics in clinical practice: lessons from the front linesHoward J Jacob, Kelly Abrams, David P Bick, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Pageof 40